Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
出版年份 2017 全文链接
标题
Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume 30, Issue 11, Pages 1516-1526
出版商
Springer Nature
发表日期
2017-07-28
DOI
10.1038/modpathol.2017.86
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies
- (2016) T. M. Shaver et al. CANCER RESEARCH
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Malignant Melanoma of the Nail Apparatus
- (2016) Ryan C. Romano et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Cytogenetic Analysis of JAZF1, PHF1, and YWHAE in Endometrial Stromal Tumors
- (2016) Jennelle C. Hodge et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
- (2016) Woo Young Sun et al. Journal of Translational Medicine
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
- (2016) Justin M. Balko et al. Science Translational Medicine
- Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
- (2016) Mehrad Tavallai et al. Oncotarget
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes
- (2015) Hee Jin Lee et al. BREAST CANCER RESEARCH AND TREATMENT
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
- (2015) F. Sabbatino et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antagonists of PD-1 and PD-L1 in Cancer Treatment
- (2015) Evan J. Lipson et al. SEMINARS IN ONCOLOGY
- Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer
- (2015) Min Soo Kim et al. Oncotarget
- Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
- (2015) Michael T. Barrett et al. Oncotarget
- Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
- (2014) Y. Hao et al. CLINICAL CANCER RESEARCH
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts
- (2014) Anton Neschadim et al. ENDOCRINE-RELATED CANCER
- Targeting the relaxin hormonal pathway in prostate cancer
- (2014) Anton Neschadim et al. INTERNATIONAL JOURNAL OF CANCER
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
- (2014) Hatem Soliman et al. PLoS One
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma
- (2012) Yanli Luo et al. PATHOLOGY & ONCOLOGY RESEARCH
- Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
- (2011) H. Xin et al. CANCER RESEARCH
- Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy
- (2011) Chun Hing Tse et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and functional analysis of 9p24 amplified genes in human breast cancer
- (2011) J Wu et al. ONCOGENE
- Advancing a clinically relevant perspective of the clonal nature of cancer
- (2011) C. Ruiz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome
- (2010) Matthias Choschzick et al. MODERN PATHOLOGY
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
- (2009) F. Andre et al. CLINICAL CANCER RESEARCH
- Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
- (2009) I-Tien Yeh et al. MODERN PATHOLOGY
- Triple-Negative Breast Cancer: Risk Factors to Potential Targets
- (2008) B. P. Schneider et al. CLINICAL CANCER RESEARCH
- Polysomy 17 and HER-2 Amplification: True, True, and Unrelated
- (2008) Carol L. Rosenberg JOURNAL OF CLINICAL ONCOLOGY
- Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
- (2008) Isabelle Vanden Bempt et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More